Best practices for long-term monitoring and follow-up of Alemtuzumab-Treated MS patients in real-world clinical settings

Barclay, Krista and Carruthers, Robert and Traboulsee, Anthony and Bass, Ann D. and LaGanke, Christopher and Bertolotto, Antonio and Boster, Aaron and Celius, Elisabeth G. and Seze, Jérôme de and Cruz, Dionisio Dela and Habek, Mario and Lee, Jong-Mi and Limmroth, Volker and Meuth, Sven G. and Oreja-Guevara, Celia and Pagnotta, Patricia and Vos, Cindy and Ziemssen, Tjalf and Baker, Darren P. and Wijmeersch, Bart Van (2019) Best practices for long-term monitoring and follow-up of Alemtuzumab-Treated MS patients in real-world clinical settings. Frontiers in Neurology, 10. ISSN 1664-2295

PDF - Published Version Download (2MB)

Abstract

Multiple sclerosis (MS) is a chronic autoimmune neurological disease that typically affects young adults, causing irreversible physical disability and cognitive impairment. Alemtuzumab, administered intravenously as 2 initial courses of 12 mg/day (5 consecutive days at baseline, and 3 consecutive days 12 months later), resulted in significantly greater improvements in clinical and MRI outcomes vs. subcutaneous interferon beta-1a over 2 years in patients with active relapsing-remitting MS (RRMS) who were either treatment-naive (CARE-MS I; NCT00530348) or had an inadequate response to prior therapy (CARE-MS II; NCT00548405). Efficacy with alemtuzumab was maintained over 7 years in subsequent extension studies (NCT00930553; NCT02255656), in the absence of continuous treatment and with a consistent safety profile. There is an increased incidence of autoimmune events in patients treated with alemtuzumab (mainly thyroid events, but also immune thrombocytopenia and nephropathy), which imparts a need for mandatory safety monitoring for 4 years following the last treatment. The risk management strategy for alemtuzumab-treated patients includes laboratory monitoring and a comprehensive patient education and support program that enables early detection and effective management of autoimmune events, yielding optimal outcomes for MS patients. Here we provide an overview of tools and techniques that have been implemented in real-world clinical settings to reduce the burden of monitoring for both patients and healthcare providers, including customized educational materials, the use of social media, and interactive online databases for managing healthcare data. Many practices are also enhancing patient outreach efforts through coordination with specialized nursing services and ancillary caregivers. The best practice recommendations for safety monitoring described in this article, based on experiences in real-world clinical settings, may enable early detection and management of autoimmune events, and help with implementation of monitoring requirements while maximizing the benefits of alemtuzumab treatment for MS patients.

Actions (login required)

View Item

Downloads